Sinopharm Sinlite's Hong Kong IPO Prospectus Expires on August 12
According to Zhitong Finance, Sinopharm Sinlite's (002294.SZ) Hong Kong IPO prospectus, originally submitted on February 12, 2026, expired on August 12, 2026. Goldman Sachs, Citigroup, and CITIC Securities served as joint sponsors of the listing. Sinlite is a leading pharmaceutical enterprise in cardiovascular-renal-metabolic syndrome treatment, and was ranked as China's second-largest innovative drug company in the cardiovascular sector by revenue in 2024, according to Frost & Sullivan.
GateNews·08-11 22:41
